Factor VLeiden and Prothrombin G20210A Gene Polymorphisms in Patients with Coronary Artery Disease
Open Access
- 1 January 2008
- journal article
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 49 (2), 237-243
- https://doi.org/10.3349/ymj.2008.49.2.237
Abstract
The precise molecular mechanisms culminating in coronary artery disease (CAD) are not well understood, despite a wealth of knowledge on predisposing risk factors and pathomechanisms. CAD and myocardial infarction (MI) are complex genetic diseases; neither the environment alone, nor a single gene, cause disease, rather, a mix of environmental and genetic factors lead to atherosclerosis of the coronary arteries. In the present study, our aim was to investigate the roles of prothrombin G20210A mutation and Factor VLeiden mutation in atherosclerotic coronary artery disease. 287 subjects (106 control subjects, who were angiographically normal, and 181 angiographically documented coronary atherosclerotic patients who exhibited coronary artery narrowing to a degree of ≥ 50%) were included in this study. The mutations were assessed with LightCycler Real-Time PCR mutation detection kits (Roche Diagnostics, GmbH, Germany). 6.6% of control subjects, and 6.1% of patients with (50% coronary artery narrowing were determined to have the Factor VLeiden heterozygote mutation. 6.6% of control subjects had the Prothrombin G20210A heterozygote mutation, while 7.7% of patients with (50% coronary artery narrowing had this mutation. The OR for Factor VLeiden was 1.52 (CI: 0.240 - 9.602) and for Prothrombin G20210A mutation, the OR was 1.415 (CI: 0.287 - 6.962). Although both the heterozygote Factor VLeiden and Prothrombin gene mutations were more frequent in patients with CAD than in control subjects, there was no statistical relationship found to exist between coronary artery disease and the Factor VLeiden and Prothrombin G20210A mutations.Keywords
This publication has 42 references indexed in Scilit:
- Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analysesBlood, 2002
- Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of diseaseEuropean Heart Journal, 2002
- Factor V Leiden and its relation to left ventricular thrombus in acute myocardial infarctionActa Cardiologica, 2001
- Risk of Stroke in Young Women and Two Prothrombotic Mutations: Factor V Leiden and Prothrombin Gene Variant (G20210A)Stroke, 1998
- The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic diseaseBritish Journal of Haematology, 1997
- Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countriesJournal of Internal Medicine, 1996
- No association of APC resistance with myocardial infarctionBlood Coagulation & Fibrinolysis, 1995
- Increased frequency of a mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery diseaseAtherosclerosis, 1995
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993